OURA ring wearable monitoring for adults with myelodysplastic syndromes
OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study
This pilot will test whether adults with MDS can wear an OURA ring regularly and upload biometric data so clinicians can link those measurements with quality of life and transfusion status.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sunnybrook Health Sciences Centre Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT06270771 on ClinicalTrials.gov |
What this trial studies
This single-center, single-arm feasibility pilot will enroll two cohorts (transfusion-dependent and non-transfusion-dependent MDS), each planned for 30 participants, who will be provided an OURA ring and training. Participants will wear the ring, sync data to a smartphone app, and upload biometrics weekly while completing clinical assessments and quality-of-life questionnaires at baseline and follow-up visits. The study will collect baseline demographics, disease characteristics, laboratory values, and standardized patient-reported outcome measures to correlate with ring-derived metrics. The primary feasibility hypothesis is that participants will wear the ring at least 70% of the time over a three-month period.
Who should consider this trial
Good fit: Adults (18+) with a WHO 2022 diagnosis of MDS of any risk group who can wear a ring, operate a compatible smartphone app, and are willing to upload data—including both transfusion-dependent and non-transfusion-dependent patients with ECOG performance status ≤3—are ideal candidates.
Not a fit: Patients with ECOG >3 or with cognitive or physical impairments that prevent using the ring or smartphone are unlikely to be able to participate or derive benefit from this wearable-based monitoring.
Why it matters
Potential benefit: If successful, this approach could provide passive, continuous data on sleep, activity, and physiologic metrics that help detect symptom changes or declines in quality of life earlier than periodic clinic visits.
How similar studies have performed: Wearable devices have shown promise in other cancer and chronic disease populations for linking activity and sleep patterns to symptoms and outcomes, but using the OURA ring specifically in MDS is largely novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged 18 or older 4. Able to read, write and speak English or French (non-English or French speaking patients may participate if appropriate translation is used) 5. Diagnosed with Myelodysplastic Syndrome using WHO 2022 criteria (12) all risk groups 6. Ability to wear the OURA ring and operate the associated smart-phone app, and willing to adhere to the study regimen Exclusion Criteria: 1. Performance status ECOG \> 3. 2. Cognitive or physical impairment preventing the usage or utilization of the OURA ring and smart phone.
Where this trial is running
Toronto, Ontario
- Sunnybrook Health Sciences Research Centre — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: Dr. Rena Buckstein, MD
- Email: rena.buckstein@sunnybrook.ca
- Phone: 416-480-5000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.